IceCure Medical (ICCM) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for minimally invasive tumor treatment across multiple indications, with ProSense as the lead product.

• Submitted ICE3 breast cancer trial data to the FDA, seeking marketing authorization for early-stage breast cancer; favorable advisory panel review and ongoing post-market study planning.

• Incorporated in Israel, listed on Nasdaq and TASE, with global operations and subsidiaries in the US, Hong Kong, and China.

Financial performance and metrics

• Product sales for the three and six months ended June 30, 2025, were approximately $525,000 and $1.25 million, respectively.

• As of March 31, 2025, had $6.0 million in cash and cash equivalents and an accumulated deficit of $109.0 million.

• Net proceeds from the fully subscribed offering expected to be approximately $9.3 million after fees and expenses.

Use of proceeds and capital allocation

• Net proceeds, together with existing cash, will be used to repay a $2 million bridge loan from Epoch and for general corporate and working capital purposes.

• Management retains broad discretion over allocation of net proceeds.